Verastem (VSTM) Income from Continuing Operations (2011 - 2026)
Verastem's (VSTM) quarterly Income from Continuing Operations came in at 44455000.0 in Q1 2026, little changed year-on-year from 44504108.26 in Q1 2025, and down 1487.92% quarter-over-quarter from 3203000.0 in Q4 2025.
Verastem (VSTM) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Verastem's Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 44455000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations changed 0.11% year-over-year to 44455000.0 in Q1 2026; TTM through Mar 2026 was 139479000.0, a 5.54% decrease from a year earlier, with the FY2025 full-year figure at 165482000.0, down 26.66% from the prior year.
- Income from Continuing Operations fell to 44455000.0 in Q1 2026 per VSTM's latest filing, from 3203000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3203000.0 in Q4 2025 and bottomed at 53951000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 21958000.0 (2022), against an average of 27424352.94.
- Biggest YoY gain for Income from Continuing Operations was 110.02% in 2025; the steepest drop was 192.7% in 2025.
- Year by year, Income from Continuing Operations stood at 16801000.0 in 2022, then plunged by 76.25% to 29612000.0 in 2023, then retreated by 7.96% to 31968000.0 in 2024, then soared by 110.02% to 3203000.0 in 2025, then tumbled by 1487.92% to 44455000.0 in 2026.
- Per Business Quant, the three latest VSTM Income from Continuing Operations figures stand at 44455000.0 (Q1 2026), 3203000.0 (Q4 2025), and 44276000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Verastem | 166.09 Mn | -31.73 Mn | 15.90 Mn | -44.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.46 Mn |
| Dec 31, 2025 | 3.20 Mn |
| Sep 30, 2025 | -44.28 Mn |
| Jun 30, 2025 | -53.95 Mn |
| Mar 31, 2025 | -44.41 Mn |
| Dec 31, 2024 | -31.97 Mn |
| Sep 30, 2024 | -37.35 Mn |
| Jun 30, 2024 | -18.43 Mn |
| Mar 31, 2024 | -31.23 Mn |
| Dec 31, 2023 | -29.61 Mn |
| Sep 30, 2023 | -20.19 Mn |
| Jun 30, 2023 | -20.29 Mn |
| Mar 31, 2023 | -19.14 Mn |
| Dec 31, 2022 | -16.80 Mn |
| Sep 30, 2022 | -18.17 Mn |
| Jun 30, 2022 | -21.96 Mn |
| Mar 31, 2022 | -17.19 Mn |
| Dec 31, 2021 | -16.48 Mn |
| Sep 30, 2021 | -24.95 Mn |
| Jun 30, 2021 | -34.78 Mn |